document type sequence filename description text html head title title head body bgcolor white style margin margin bottom font size font family time roman align right exhibit style margin margin bottom font size font family time roman align center certain material indicated asterisk been omitted from this document pursuant request confidential treatment omitted material been filed separately with security exchange commission style margin margin bottom font size font family time roman align center first amendment style margin margin bottom font size font family time roman align center license agreement style margin margin bottom text indent font size font family time roman this first amendment effective october effective date that certain license agreement dated september nbsp license agreement between prometheus laboratory prometheus cypress bioscience successor interest proprius which subsequently assigned exagen diagnostics exagen prometheus exagen each sometimes referred individually party together party capitalized term defined herein shall have meaning ascribed them license agreement style margin margin bottom text indent font size font family time roman small hereas small prometheus exagen wish amend license agreement with regard development clinical testing activity marketing milestone royalty described below otherwise amend license agreement term forth herein style margin margin bottom text indent font size font family time roman small small small herefore small party hereby agree following style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width nbsp width valign align left align left valign reference proprius agreement shall understood reference exagen table style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width nbsp width valign align left align left valign section nbsp development clinical testing activity shall deleted entirety replaced with following table style margin margin bottom text indent font size font family time roman development clinical testing activity exagen shall reasonable commercial effort undertake development activity licensed product including limited conducting having conducted completing having completed nbsp those three nbsp clinical study described exhibit hereto nbsp dossier used communication with managed care entity that explains advantageous pharmacoeconomics associated with licensed product later than march nbsp exagen shall bear cost expense related development activity forth above licensed product exagen acknowledges agrees that these development activity critical commercial success licensed product agrees that should exagen fail timely complete dossier described section nbsp this section timely accomplish those three nbsp clinical study described exhibit exagen will prometheus time payment fifty thousand dollar addition applicable exagen shall reasonable commercial effort undertake other development activity licensed product required approval from applicable regulatory authority exagen shall bear cost expense related development licensed product style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width nbsp width valign align left align left valign section nbsp licensed product development marketing shall deleted entirety replaced with following table style margin margin bottom text indent font size font family time roman licensed product development marketing exagen shall reasonable commercial effort itself affiliate through sublicensee develop market sell licensed product united state exagen shall also reasonable commercial effort develop licensed product such other region territory style margin margin bottom font size nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width valign align left align left valign certain information this page been omitted filed separately with security exchange commission confidential treatment been requested with respect omitted portion table style page break before always size style color width align center style margin margin bottom font size font family time roman exagen deems commercially reasonable market sell licensed product region territory where appropriate regulatory marketing approval have been obtained from applicable regulatory authority exagen exagen expense applicable sublicensee expense shall responsible development commercial activity expense related undertaking obligation pursuant this section nbsp avoidance doubt reasonable commercial effort commercialize licensed product shall include compensation structure applicable member exagen sale force that responsible detailing licensed product each sale representative with variable incentive compensation component based promotion licensed product described below style margin margin bottom text indent font size font family time roman least annual targeted incentive compensation percentage each sale representative first style font size vertical align nbsp year beginning january nbsp shall based performance related minimum detail minimum sale achievement licensed product where detail defined interactive face face visit territory sale representative with physician legally empowered designee during which indicated other relevant characteristic licensed product described such sale representative fair balanced manner consistent with applicable however incidental contact between such sale representative physician will constitute detail sale achievement defined actual sale licensed product compared commercially reasonable sale goal prescribed each individual geographic territory style margin margin bottom text indent font size font family time roman least incentive compensation percentage each sale representative second style font size vertical align nbsp year january following effective date year thereafter which there exists valid claim licensed product shall based performance related detailing product style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width nbsp width valign align left align left valign section nbsp milestone payment shall deleted entirety replaced with following table style margin margin bottom text indent font size font family time roman milestone payment addition payment described section this agreement exagen shall make following time cash milestone payment prometheus within ninety nbsp occurrence event style font size margin margin bottom nbsp table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width style font family time roman font size valign bottom nowrap style border bottom solid width font size font family time roman milestone event valign bottom nbsp nbsp valign bottom colspan align center style border bottom solid payment valign bottom nbsp style font family time roman font size valign style margin left text indent font size font family time roman achievement greater than equal cumulative sale licensed product determined aggregate sale exagen affiliate sublicensees valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp table style margin margin bottom font size font family time roman avoidance doubt license agreement amended remove concept milestone payment reference that term concept hereby deleted including limited reference section nbsp style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width nbsp width valign align left align left valign section nbsp royalty payment prometheus shall deleted entirety replaced with following table style margin margin bottom font size nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width valign align left align left valign certain information this page been omitted filed separately with security exchange commission confidential treatment been requested with respect omitted portion table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman royalty payment prometheus partial consideration license right granted exagen hereunder exagen shall prometheus royalty based sale licensed product exagen affiliate sublicenses country where valid claim patent right covering such licensed product exists royalty rate forth below style font size margin margin bottom nbsp table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width style font family time roman font size valign bottom nowrap style border bottom solid width font size font family time roman sale valign bottom nbsp nbsp valign bottom colspan align center style border bottom solid royalty nbsp rate valign bottom nbsp style font family time roman font size valign style margin left text indent font size font family time roman annual sale calendar year than valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp style font family time roman font size valign style margin left text indent font size font family time roman annual sale calendar year equal greater than than valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp style font family time roman font size valign style margin left text indent font size font family time roman annual sale calendar year equal greater than valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp table style margin margin bottom font size font family time roman subject termination provision article this agreement exagen obligation royalty prometheus licensed product covered valid claim patent right each country shall expire date when last patent containing valid claim such country expires lapse invalidated style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width nbsp width valign align left align left valign except expressly amended this first amendment term provision license agreement shall remain full force effect table style margin margin bottom text indent font size font family time roman witness whereof party have executed this first amendment date first forth above style font size margin margin bottom nbsp table cellspacing cellpadding width border style border collapse collapse font family time roman font size width valign bottom width width valign bottom width width valign bottom width width valign bottom width width style font family time roman font size valign colspan exagen diagnostics valign bottom nbsp valign valign bottom nbsp valign colspan prometheus laboratory style font size height colspan height colspan height colspan style font family time roman font size valign colspan style margin margin bottom border bottom solid font size font family time roman rocca valign bottom nbsp valign valign bottom nbsp valign colspan style margin margin bottom border bottom solid font size font family time roman lisa miller style font family time roman font size valign name valign bottom nbsp valign rocca valign bottom nbsp valign valign bottom nbsp valign name valign bottom nbsp valign lisa miller style font family time roman font size valign title valign bottom nbsp valign president valign bottom nbsp valign valign bottom nbsp valign title valign bottom nbsp valign president style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign colspan approved legal dept prometheus laboratory nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign colspan approved finance dept prometheus laboratory nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp table style margin margin bottom font size nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width valign align left align left valign certain information this page been omitted filed separately with security exchange commission confidential treatment been requested with respect omitted portion table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman align center exhibit style margin margin bottom font size font family time roman align center clinical study style margin margin bottom font size font family time roman avise participating clinical trial style font size margin margin bottom nbsp table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width valign bottom width width valign bottom width width valign bottom width width valign bottom width width style font family time roman font size valign bottom nowrap style border bottom solid width font size font family time roman sponsor valign bottom nbsp nbsp valign bottom nowrap style border bottom solid width font size font family time roman title valign bottom nbsp nbsp valign bottom nowrap style border bottom solid width font size font family time roman purpose valign bottom nbsp nbsp valign bottom nowrap style margin margin bottom font size font family time roman subject style margin margin bottom border bottom solid width font size font family time roman timeline valign bottom nbsp nbsp valign bottom nowrap style border bottom solid width font size font family time roman exagen role valign bottom nbsp nbsp valign bottom nowrap style border bottom solid width font size font family time roman comment style font size height height colspan height colspan height colspan height colspan height colspan style font family time roman font size valign university alabama birmingham valign bottom nbsp nbsp valign treatment efficacy toxicity rheumatoid arthritis database repository valign bottom nbsp nbsp valign stimulate collaborative effort federal funding agency voluntary health agency professional organization industry partner enable creation large sustainable database repository better understand molecular basis treatment rapidly accelerate translational research valign bottom nbsp nbsp valign style margin margin bottom font size font family time roman style margin margin bottom font size font family time roman february august valign bottom nbsp nbsp valign provide methotrexate polyglutamate concentration testing valign bottom nbsp nbsp valign exagen performed mtxpg testing from february june style font size height height colspan height colspan height colspan height colspan height colspan style font family time roman font size valign pfizer valign bottom nbsp nbsp valign randomized double blind placebo controlled study safety valign bottom nbsp nbsp valign first week this study will compare efficacy etanercept once valign bottom nbsp nbsp valign style margin margin bottom font size font family time roman style margin margin bottom font size font family time roman august valign bottom nbsp nbsp valign provide methotrexage polyglutamate concentration testing valign bottom nbsp nbsp valign table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width valign bottom width width valign bottom width width valign bottom width width valign bottom width width style font family time roman font size valign valign bottom font style font size nbsp nbsp font valign efficacy etanercept subject with rheumatoid arthritis have inadequate response adalimumab infliximab plus methotrexate valign bottom font style font size nbsp nbsp font valign weekly placebo subject with rheumatoid arthritis have responded well infliximab adalimumab plus methotrexate this comparison will performed subject separately subject anti drug antibody positive these medication from week week subject will receive etanercept once weekly effect anti drug antibody status efficacy etanercept well safety profile etanercept these subject will also evaluated valign bottom font style font size nbsp nbsp font valign valign bottom font style font size nbsp nbsp font valign valign bottom font style font size nbsp nbsp font valign table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width valign bottom width width valign bottom width width valign bottom width width valign bottom width width style font family time roman font size valign valign bottom font style font size nbsp nbsp font valign valign bottom font style font size nbsp nbsp font valign throughout study valign bottom font style font size nbsp nbsp font valign valign bottom font style font size nbsp nbsp font valign valign bottom font style font size nbsp nbsp font valign style font size height height colspan height colspan height colspan height colspan height colspan style font family time roman font size valign keio university valign bottom font style font size nbsp nbsp font valign style margin margin bottom font size font family time roman magik study style margin margin bottom font size font family time roman ethotrexate nchor drug japanese rheumatoid arthritis monitored erythrocyte polyglutamate concentration rheumatology expert meeting valign bottom font style font size nbsp nbsp font valign proportion japanese patient with rheumatoid arthritis treated quite will with rather dose methotrexate sometimes week suppose that mtxpg concentration reach point which rheumatoid arthritis should controlled have reported with lower dose japanese than caucasian like prove this establish optimal usage japanese patient valign bottom font style font size nbsp nbsp font valign style margin margin bottom font size font family time roman style margin margin bottom font size font family time roman september valign bottom font style font size nbsp nbsp font valign provide methotrexage polyglutamate concentration testing valign bottom font style font size nbsp nbsp font valign subject have been enrolled table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center body html text document